GeneSpector was created during the covid-19 epidemic to help the pandemic situation by developing, producing and implementing PCR diagnostics for Czech laboratories and hospitals. Over time, the company established the own positioning as an incubator and accelerator driving innovative ideas in clinical diagnostics from discovery to proof-of-concept. The proprietary approaches are commercialized through either licensing to industry leaders or the formation of focused spin-off ventures with dedicated research and business development teams.
Partnering Options
We are looking for partners from different segments (Academia, Hospitals, Commercial, Investments and others) to help us realize our vision. We are forming Ventures to bring important and often patented technologies with a huge potential to the global market. These operate with our support, but also have their own team of professionals who steer their companies towards their goals in a start-up setting. We are looking for investors and partners for them.
Our Cap Table
GeneSpector is a spin-off of Charles University, which through its subsidiary Charles University Innovations Prague owns the largest share. The co-founders are SPADIA LAB, one of the largest clinical laboratories in the Czech Republic, and subsequently mikeVision, led by Michal Pohludka, who has also been the CEO of GeneSpector since the beginning. Over time, Martin Radina, who as co-owner of SPADIA LAB is experienced in the field of clinical diagnostics, joined the company in a minority way, strengthening his involvement in the company's activities.